GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 ...

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a ...

Natural killer (NK) cells constitute the third largest lymphocyte subset, representing around 10-15% of circulating lymphocytes in blood. These large granular cells are essential to the immune ...

As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated ...

In this compelling episode of The Ellis Martin Report, host Ellis Martin engages in a powerful and enlightening conversation with Michael Breen, ...

GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing ...

Researchers at MD Anderson Cancer Center at the University of Texas, Houston, are conducting numerous trials of natural killer (NK) cells, and gave an update at the recent Combined CAR-T Congress ...

Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move ...

Presenting at Technology Networks’<i/> Cell and Gene Therapy 2025 Symposium, Dr. Andrew Mancini, senior corporate development ...

Discover the healing art of Forest Bathing or Shinrin-yoku. Learn about its origins in Japan and its profound health benefits like stress reduction and improved mood.

Fintel reports that on May 20, 2025, Piper Sandler upgraded their outlook for ImmunityBio (NasdaqGS:IBRX) from Neutral to ...

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) ...